According to the National Academy of Sciences , Philip Needleman , who was vice president of Monsanto in 1989 and president of Searle in 1993  oversaw research into COX-2 that led to the development of the anti-inflammatory drug celecoxib (Celebrex).  He became senior executive vice president and chief scientist of Pharmacia from 2000 to 2003.  Celecoxib was discovered and  developed by G. D. Searle & Company and was approved by the FDA on December 31, 1998.  It was co-promoted by Monsanto Company (parent company of Searle) and Pfizer under the brand name Celebrex. Monsanto merged with Pharmacia , from which the Medical Research Division was acquired by Pfizer, giving Pfizer ownership of Celebrex. The drug was at the core of a major patent dispute that was resolved in Searle's favor (later Pfizer) in 2004.   In University of Rochester v. Searle & Co. , 358 916 (Fed. Cir. 2004), the University of Rochester claimed that United States Pat. No. 6,048,850 (which claimed a method of inhibiting COX-2 in humans using a compound, without actually disclosing what that compound might be) covered drugs such as celecoxib. The court ruled in favor of Searle, holding in essence that the University had claimed a method requiring, yet provided no written description of, a compound that could inhibit COX-2 and therefore the patent was invalid.